NCT02040597View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Beclometasone/Formoterol/Glycopyrrolate

Trial Locations (2)

05-830

Biovirtus Research Site, Nadarzyn

90-153

Medical University in Lodz, Lodz

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02040597 - A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. | Biotech Hunter | Biotech Hunter